Navelbine (Vinorelbine Tartrate)

Vinorelbine, the active ingredient in Navelbine, is a Vinca alkaloid presented as an injectable solution for intravenous use. It is employed in the treatment of certain solid tumours, notably non‑small cell lung cancer and breast cancer, in adult patients.

GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Vinorelbine is used in oncology to target rapidly dividing cancer cells in specific tumour types.

- Non‑small cell lung cancer: improves disease control and extends survival when used in combination chemotherapy. - Breast cancer: contributes to tumour reduction and progression delay in metastatic or advanced disease. - Metastatic breast cancer: administered as part of multi‑agent regimens to enhance overall response rates.

Vinorelbine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Anemia: decreased red blood cells causing fatigue. - Nausea: sensation of urge to vomit. - Vomiting: expulsion of stomach contents. - Constipation: difficulty passing stools. - Alopecia: hair loss on scalp and body.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Pulmonary toxicity: inflammation or fibrosis of lung tissue. - Peripheral neuropathy: tingling or numbness in extremities. - Severe hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Cardiac toxicity: arrhythmias or reduced cardiac function.

When using Vinorelbine, clinicians should observe several safety measures to minimise risk.

- Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia. - Assess liver function: evaluate hepatic enzymes before and during therapy. - Evaluate neuropathy: avoid in patients with pre‑existing peripheral nerve disorders. - Avoid concurrent myelosuppressive agents: limit additive bone‑marrow toxicity. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase vinorelbine exposure and toxicity. - Strong CYP3A4 inducers (e.g., rifampin): reduce therapeutic levels. - Concurrent myelosuppressive chemotherapy: heighten risk of severe bone‑marrow suppression. - Other vinca alkaloids: additive neurotoxicity. - Monoclonal antibodies affecting bone marrow (e.g., bevacizumab): increase hematologic toxicity.

Moderate Interactions (Monitor Closely): - Antiemetics such as ondansetron: may affect QT interval. - Anticoagulants (warfarin): monitor INR for bleeding risk. - CYP3A4 substrate drugs (e.g., midazolam): possible altered metabolism. - Diuretics: watch electrolyte balance. - NSAIDs: increased risk of gastrointestinal bleeding.